Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer

被引：0

作者：

Takayuki Iwamoto

Naoki Niikura

Kenichi Watanabe

Takashi Takeshita

Yuichiro Kikawa

Kokoro Kobayashi

Nobutaka Iwakuma

Takuho Okamura

Hiroshi Tada

Shinji Ozaki

Toshitaka Okuno

Uhi Toh

Yutaka Yamamoto

Michiko Tsuneizumi

Hiroshi Ishiguro

Norikazu Masuda

Shigehira Saji

机构：

[1] Kawasaki Medical School Hospital,Breast and Thyroid Surgery

[2] Okayama University Hospital,Breast and Endocrine Surgery

[3] Tokai University School of Medicine,Department of Breast Oncology

[4] Hokkaido Cancer Center,Breast Surgery

[5] Kumamoto City Hospital,Breast and Endocrine Surgery

[6] Kansai Medical University Hospital,Department of Breast Surgery

[7] Saitama Red Cross Hospital,Department of Medical Oncology

[8] Kyushu Medical Center,Breast Center, Department of Breast Surgery

[9] Tohoku University Hospital,Department of Surgery, Division of Breast and Endocrine Surgery

[10] Hiroshima Prefectural Hospital,Department of Gastrointestinal and Breast Surgery

[11] Kobe City Nishi-Kobe Medical Center,Department of Breast Surgery

[12] Kurume University Hospital,Department of Breast Surgery

[13] Kumamoto University Hospital,Department of Breast and Endocrine Surgery

[14] Shizuoka General Hospital,Department of Breast Surgery

[15] Saitama Medical University International Medical Center,Breast Oncology Service

[16] Nagoya University Graduate School of Medicine,Department of Breast and Endocrine Surgery

[17] Fukushima Medical University School of Medicine,Department of Medical Oncology

来源：

Breast Cancer Research and Treatment | 2024年 / 203卷

关键词：

Advanced breast cancer; Palbociclib; Fulvestrant; Cell-free DNA; Window of opportunity;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：225 / 234

页数：9

共 50 条

[21] Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer
Pauline du Rusquec
Clément Palpacuer
Loic Campion
Anne Patsouris
Paule Augereau
Carole Gourmelon
Marie Robert
Laurence Dumas
Folliard Caroline
Mario Campone
Jean-Sébastien Frenel
Breast Cancer Research and Treatment, 2018, 168 : 559 - 566
[22] Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer
du Rusquec, Pauline
Palpacuer, Clement
Campion, Loic
Patsouris, Anne
Augereau, Paule
Gourmelon, Carole
Robert, Marie
Dumas, Laurence
Caroline, Folliard
Campone, Mario
Frenel, Jean-Sebastien
BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : 559 - 566
[23] Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
Gelmon, Karen A.
Cristofanilli, Massimo
Rugo, Hope S.
DeMichele, Angela M.
Joy, Anil A.
Castrellon, Aurelio
Sleckman, Bethany
Mori, Ave
Theall, Kathy Puyana
Lu, Dongrui R.
Huang, Xin
Bananis, Eustratios
Finn, Richard S.
Slamon, Dennis J.
BREAST JOURNAL, 2020, 26 (03) : 368 - 375
[24] Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
Patrick Neven
Hope S. Rugo
Sara M. Tolaney
Hiroji Iwata
Masakazu Toi
Matthew P. Goetz
Peter A. Kaufman
Yi Lu
Nadine Haddad
Karla C. Hurt
George W. Sledge
Breast Cancer Research, 23
[25] Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Slamon, Dennis J.
Neven, Patrick
Chia, Stephen
Fasching, Peter A.
De Laurentiis, Michelino
Im, Seock-Ah
Petrakova, Katarina
Bianchi, Giulia Val
Esteva, Francisco J.
Martin, Miguel
Nusch, Arnd
Sonke, Gabe S.
De la Cruz-Merino, Luis
Beck, J. Thaddeus
Pivot, Xavier
Vidam, Gena
Wang, Yingbo
Lorenc, Karen Rodriguez
Miller, Michelle
Taran, Tetiana
Jerusalem, Guy
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (24) : 2465 - +
[26] Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review
Gayathri Nagaraj
Cynthia X. Ma
Advances in Therapy, 2021, 38 : 109 - 136
[27] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
Hugo Herrscher
Michel Velten
Julie Leblanc
Michal Kalish-Weindling
Cathie Fischbach
Delphine Exinger
Xavier Pivot
Thierry Petit
Breast Cancer Research and Treatment, 2020, 179 : 371 - 376
[28] Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review
Nagaraj, Gayathri
Ma, Cynthia X.
ADVANCES IN THERAPY, 2021, 38 (01) : 109 - 136
[29] Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
Mukai, Hirofumi
Shimizu, Chikako
Masuda, Norikazu
Ohtani, Shoichiro
Ohno, Shinji
Takahashi, Masato
Yamamoto, Yutaka
Nishimura, Reiki
Sato, Nobuaki
Ohsumi, Shozo
Iwata, Hiroji
Mori, Yuko
Hashigaki, Satoshi
Muramatsu, Yasuaki
Nagasawa, Takashi
Umeyama, Yoshiko
Lu, Dongrui R.
Toi, Masakazu
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (03) : 274 - 287
[30] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
Herrscher, Hugo
Velten, Michel
Leblanc, Julie
Kalish-Weindling, Michal
Fischbach, Cathie
Exinger, Delphine
Pivot, Xavier
Petit, Thierry
BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (02) : 371 - 376

← 1 2 3 4 5 →